caffeine has been researched along with istradefylline in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drabczyńska, A; Karolak-Wojciechowska, J; Kieć-Kononowicz, K; Müller, CE; Schiedel, A; Schumacher, B; Yuzlenko, O | 1 |
| Drabczyńska, A; Fruziński, A; Karolak-Wojciechowska, J; Kieć-Kononowicz, K; Müller, CE; Schiedel, A; Schumacher, B; Yuzlenko, O; Zobnina, W | 1 |
| Bergh, JJ; Castagnoli, N; Malan, SF; Petzer, JP; Pretorius, J | 1 |
| Andrews, SP; Congreve, M; Errey, JC; Marshall, FH; Mason, JS; Robertson, N; Tehan, B; Weir, M; Zhukov, A | 1 |
| Drabczyńska, A; Handzlik, J; Karcz, T; Karolak-Wojciechowska, J; Kieć-Kononowicz, K; Köse, M; Kuder, K; Müller, CE; Paskaleva, M; Schiedel, AC; Yuzlenko, O | 1 |
| Capuano, B; Jörg, M; Mak, FS; Miller, ND; Scammells, PJ; Shonberg, J; Yuriev, E | 1 |
| Akkari, R; Borrmann, T; Brunschweiger, A; Drabczyńska, A; Hockemeyer, J; Kieć-Kononowicz, K; Koch, P; Köse, M; Küppers, P; Müller, CE; Radjainia, H; Schlenk, M | 1 |
| de Lera Ruiz, M; Lim, YH; Zheng, J | 1 |
| Terre'Blanche, G; Van der Walt, MM | 1 |
| Doroż-Płonka, A; Drabczyńska, A; Handzlik, J; Hinz, S; Karcz, T; Kieć-Kononowicz, K; Latacz, G; Müller, CE; Schabikowski, J; Stanuch, K; Szymańska, E; Załuski, M | 1 |
| Hinz, S; Karcz, T; Kieć-Kononowicz, K; Kubas, B; Kuder, K; Latacz, G; Müller, CE; Olejarz-Maciej, A; Schabikowski, J; Schlenk, M; Synak, D; Załuski, M; Zygmunt, M | 1 |
| Gaba, S; Gupta, GD; Monga, V; Patel, R; Saini, A; Singh, G | 1 |
| Ichikawa, S; Kitamura, S; Kuwana, Y; Nakamura, J; Shiozaki, S; Yamada, K | 1 |
| Beilstein, M; Castagnoli, K; Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Sonsalla, PK; Staal, R; Xu, K; Xu, YH | 1 |
| Gianfriddo, M; Melani, A; Pedata, F; Pugliese, AM | 1 |
| Costentin, J; El Yacoubi, M; Vaugeois, JM | 1 |
| Bastia, E; Schwarzschild, M; Xu, K | 1 |
| Chen, JF; Kalda, A; Oztas, E; Yu, L | 1 |
| Cohen-Williams, ME; Grzelak, ME; Higgins, GA; Hodgson, RA; Pond, AJ; Varty, GB | 1 |
| Jankovic, J | 1 |
| Grzelak, ME; Hodgson, RA; Hunter, JC; Parker, EM; Pond, AJ; Varty, GB | 1 |
| Collins, LE; Farrar, AM; Font, L; Nunes, EJ; Patel, V; Sager, TN; Salamone, JD; Schlar, DE | 1 |
| Agostinho, PM; Cognato, GP; Cunha, RA; Hockemeyer, J; Müller, CE; Souza, DO | 1 |
| Górska, A; Gołembiowska, K; Kamińska, K; Noworyta-Sokołowska, K; Wardas, J | 1 |
| Hok, L; Vianello, R | 1 |
4 review(s) available for caffeine and istradefylline
| Article | Year |
|---|---|
Adenosine A2A receptor as a drug discovery target.
Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Crystallography, X-Ray; Drug Discovery; Humans; Ligands; Protein Conformation; Receptor, Adenosine A2A; Signal Transduction | 2014 |
Adenosine receptor antagonists: Recent advances and therapeutic perspective.
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Structure-Activity Relationship | 2022 |
Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain; Caffeine; Central Nervous System Stimulants; Clinical Trials as Topic; Humans; Parkinson Disease; Purines; Receptors, Adenosine A2 | 2005 |
Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Central Nervous System; Clinical Trials, Phase II as Topic; Disease Models, Animal; Glutamic Acid; Humans; Inflammation; Neuroprotective Agents; Parkinson Disease; Purines | 2006 |
21 other study(ies) available for caffeine and istradefylline
| Article | Year |
|---|---|
N9-benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: synthesis and structure-activity relationships at adenosine A1 and A2A receptors.
Topics: Animals; Benzene; Chemical Phenomena; Chemistry, Physical; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Methylation; Models, Molecular; Molecular Structure; Propane; Purines; Pyrimidines; Rats; Receptor, Adenosine A1; Receptors, Adenosine A2; Structure-Activity Relationship | 2007 |
Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.
Topics: Animals; Anticonvulsants; Binding Sites; Computer Simulation; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Ligands; Male; Mice; Models, Chemical; Models, Molecular; Molecular Structure; Purines; Receptor, Adenosine A1; Receptors, Adenosine A2; Stereoisomerism; Structure-Activity Relationship | 2007 |
Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
Topics: Adenosine A2 Receptor Antagonists; Animals; Butadienes; Caffeine; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2008 |
Biophysical mapping of the adenosine A2A receptor.
Topics: Adenosine A2 Receptor Antagonists; Binding Sites; Drug Design; Ligands; Models, Molecular; Mutation; Pyrimidines; Receptor, Adenosine A2A; Small Molecule Libraries; Triazines; Triazoles; Xanthines | 2011 |
Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Cyclization; Humans; Hydrogen Bonding; Models, Molecular; Purines; Quantitative Structure-Activity Relationship; Radioligand Assay; Rats; Receptor, Adenosine A1; Receptor, Adenosine A2A | 2011 |
Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
Topics: Adenosine A2 Receptor Antagonists; Binding Sites; Humans; Hydrogen Bonding; Ligands; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Receptor, Adenosine A2A; Triazines; Triazoles | 2013 |
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; CHO Cells; Cricetulus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Purinergic P1 Receptor Antagonists; Purines; Xanthines | 2013 |
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
Topics: Adenosine A1 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Molecular Structure; Protein Binding; Receptor, Adenosine A1; Structure-Activity Relationship; Xanthines | 2015 |
Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties.
Topics: | 2018 |
Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
Topics: Adenosine A2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Ligands; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Receptor, Adenosine A2A; Structure-Activity Relationship; Xanthine | 2019 |
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Caffeine; Catalepsy; Dopamine Agents; Hypokinesia; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Reserpine; Theophylline | 1999 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Catechols; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Immunity, Innate; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines | 2001 |
A2A receptors in neuroprotection of dopaminergic neurons.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Neurons; Neuroprotective Agents; Parkinson Disease; Purines; Pyrimidines; Receptor, Adenosine A2A; Sex Factors; Triazoles | 2003 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Depression; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Haloperidol; Mice; Mice, Knockout; Motor Activity; Neurotransmitter Agents; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles | 2003 |
The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antipsychotic Agents; Attention; Caffeine; Central Nervous System Stimulants; Choice Behavior; Dopamine; Dose-Response Relationship, Drug; Male; Motor Activity; Phenethylamines; Psychomotor Performance; Purines; Rats; Reaction Time; Reflex, Startle; Xanthines | 2007 |
Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?
Topics: Adenosine A2 Receptor Antagonists; Cacao; Caffeine; Humans; Parkinson Disease; Purines; Randomized Controlled Trials as Topic; Receptors, Adenosine A2 | 2008 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Haloperidol; Neurologic Examination; Purines; Pyrimidines; Receptor, Adenosine A2A; Saimiri; Triazoles; Xanthines | 2008 |
Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Behavior, Animal; Caffeine; Central Nervous System Agents; Choice Behavior; Conditioning, Operant; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Feeding Behavior; Haloperidol; Male; Motivation; Purines; Rats; Rats, Sprague-Dawley; Reinforcement Schedule; Xanthines | 2009 |
Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Animals, Newborn; Caffeine; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Glial Fibrillary Acidic Protein; Kainic Acid; Memory Disorders; Neurotoxicity Syndromes; Phosphodiesterase Inhibitors; Purines; Pyrimidines; Qa-SNARE Proteins; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Seizures; Synapses; Synaptophysin; Synaptosomal-Associated Protein 25; Triazoles; Tritium; Xanthines | 2010 |
Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Corpus Striatum; Dopamine; Dopaminergic Neurons; Glutamic Acid; Hydroxyl Radical; Inflammation; Lipopolysaccharides; Male; Microinjections; Parkinson Disease; Purines; Rats; Receptor, Adenosine A2A | 2013 |
Selective Deuteration Improves the Affinity of Adenosine A
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Caffeine; Ligands; Receptor, Adenosine A2A | 2023 |